Saxenda for weight loss: what 8 months of liraglutide actually does

What's this video probably claiming?

Based on the caption and hashtags, @carina_och_vikten is sharing an 8-month progress update on Saxenda (liraglutide 3mg), documenting meaningful weight loss, specifically dropping below 110kg. The emotional tone, references to a "new life" around food, and language about freedom from food noise suggest she's describing the appetite-suppression effect that GLP-1 receptor agonists are known for clinically. The PCOS and lipedema hashtags are doing real work here too. Both conditions are associated with insulin resistance and disproportionate fat distribution, which can make standard caloric restriction genuinely harder. She's not selling anything obviously, and she's not claiming a cure. What she is doing is presenting her personal experience as broadly representative, which is where things get complicated. Individual response to liraglutide varies considerably, and the hashtags like nocalories could imply a zero-calorie framing that doesn't match how GLP-1 therapy actually works long-term.

What does the science actually show?

Liraglutide 3mg (Saxenda) has a reasonably solid evidence base for obesity treatment. The SCALE Obesity and Prediabetes trial, published by Pi-Sunyer et al. in 2015 in the New England Journal of Medicine, followed 3,731 adults over 56 weeks. Participants on liraglutide 3mg lost a mean of 8.4kg compared to 2.8kg on placebo. About 63% achieved at least 5% body weight reduction, and 33% lost more than 10%. Those are meaningful numbers, not transformative ones. For PCOS specifically, a 2019 meta-analysis by Siamashvili and Davis in Endocrine Reviews found GLP-1 agonists improved menstrual regularity and reduced androgen levels alongside weight loss, though sample sizes were small. For lipedema, clinical evidence is sparse. There are case reports and emerging observational data suggesting GLP-1 therapy may reduce adipose volume in some patients, but no randomized controlled trials specific to lipedema exist as of early 2025. Eight months is also a meaningful window. Liraglutide's effects often plateau between 6-12 months without dose optimization or lifestyle integration.

Where does the social media noise diverge from clinical reality?

The biggest divergence is survivorship bias. You see the 8-month success story. You don't see the people who discontinued liraglutide due to nausea, vomiting, or gallbladder issues, which occurred in roughly 3-4% of participants in SCALE trials at higher rates than placebo. You also don't see people who regained weight after stopping. The SCALE Maintenance study by Wadden et al. (2013, Obesity) showed that participants who discontinued liraglutide regained approximately two-thirds of lost weight within a year. The food freedom narrative is emotionally real for many patients, but it obscures that liraglutide's mechanism, slowing gastric emptying and reducing appetite via GLP-1 receptor activation in the hypothalamus, is pharmacologically dependent. Stop the drug, and in many cases the hunger returns. Liraglutide also requires daily subcutaneous injection, unlike weekly semaglutide, which affects adherence. And compared to semaglutide 2.4mg (Wegovy), liraglutide produces roughly half the weight loss on average, based on head-to-head data from Rubino et al. (2022, JAMA).

What should you actually know?

If you have PCOS or lipedema and you're considering GLP-1 therapy, the honest picture is this: liraglutide can work, it works better for some people than others, and it works better when prescribed and monitored by a clinician who understands your specific metabolic situation. PCOS is associated with higher rates of insulin resistance, and some evidence suggests GLP-1 agonists may address that mechanism directly beyond just caloric reduction. Lipedema is a different story. The condition involves abnormal adipose tissue that responds poorly to diet and exercise, and while anecdotal reports of GLP-1 benefit exist, nobody should be telling you it's a proven treatment for lipedema specifically. Eight months of results from one person on TikTok, however genuine, is not clinical guidance. It's also worth knowing that liraglutide is not interchangeable with semaglutide or tirzepatide. Different molecules, different receptor binding profiles, different efficacy data. Choosing between them should involve a real conversation with a prescriber who knows your history, not a hashtag comparison.